"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
| Descriptor ID |
D016729
|
| MeSH Number(s) |
D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leuprolide".
Below are MeSH descriptors whose meaning is more specific than "Leuprolide".
This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leuprolide" by people in Profiles.
-
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
-
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
-
Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 02; 13(2):169-177.
-
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203.
-
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82.
-
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer. 2016 Jun; 16(3):e61-3.
-
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 01; 33(4):332-9.
-
Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids. Mol Endocrinol. 2013 May; 27(5):726-40.
-
Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
-
Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary. 2010; 13(1):54-9.